Skip to main content
i/Blue Imaging System™ for Bladder CancerNews & Press Releases

Imagin Announces i/Blue Product Development Program Moves to University of Rochester Laboratory for Laser Energetics (LLE)

By 12 April 2016August 11th, 2022No Comments

Vancouver, B.C. and Boston, MA, April 12, 2016 – Imagin Medical (CSE: IME) (the “Company”) announced today that Dr. Stavros Demos, the inventor of the i/Blue Imaging System, has accepted the position of “Senior Scientist and Group Leader of the Optical Materials Group” at the University of Rochester Laboratory for Laser Energetics (LLE) in New York. LLE has a world class reputation for developing successful laser and optical technologies and supporting a variety of US Government missions. Going forward, Imagin Medical’s engineering team will work with LLE to continue development of its ultrasensitive cancer imaging technology. 

“Being able to work with such an extraordinary pool of scientists and engineers in their state-of-the-art facility is a great opportunity for us,” said Jim Hutchens, Imagin President and CEO. “Their expertise and success with laser and optical technology applications will help drive our development program more rapidly and may result in additional intellectual property.” 

LLE was established in 1970 and has become an internationally known resource for research and education in science and technology. A pioneer in university/industry collaborations, LLE employs over 300 engineers and scientists with a recognized expertise in laser, optics and the interaction of light with matter. 

Imagin’s goal at University of Rochester LLE is to build on the Company’s initial prototype and continue to refine the product’s design, requalifying the system’s optical model, components and advanced light sensors, and help create the controls needed for optimized operation and patient safety. These next generation products will be used for clinical trials, regulatory submission and eventual commercial distribution. 

During Imagin’s first development meeting held at LLE in Rochester, NY, Dr. Demos commented, “Working at Lawrence Livermore National Laboratory (LLNL) in California for twelve years was an invaluable experience while focusing on contributing to LLNL mission and goals. Now, at LLE, I’m joining former colleagues and collaborators, along with a world class team of scientists and their Medical Center, that can be a great asset in the efforts to continue the development of Imagin’s i/Blue Imaging System.” 

About Imagin Medical 

Imagin Medical is developing imaging solutions for the early detection of cancer. The Company is focused on advanced medical imaging to radically improve the way physicians detect cancer through the use of endoscopes. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. 

This advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. 

Learn more at 

The photo shows the Imagin team, including (from left) Steve Ruggles, Director of Quality Assurance and Regulatory Affairs; Dr. Stavros Demos, Inventor and Scientific/Technology Advisor; Jim Hutchens, President & CEO; Mike Vergano, Director of Operations. 


Jim Hutchens, 

President & CEO 

For further information, contact: 

Bill Galine, Investor Relations 

Telephone: (775) 737-3292 

Email: [email protected] 

CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. 

This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations. 

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.